1. Chen H, Zhan Y, Zhang K, Gao Y, Chen L, Zhan J, Chen Z, Zeng Z. The Global, Regional, and National Burden and Trends of Infective Endocarditis From 1990 to 2019: Results From the
Global Burden of Disease Study 2019. Front Med (Lausanne). 2022 Mar 9;9:774224. doi: 10.3389/fmed.2022.774224. PMID: 35355601; PMCID: PMC8959916.
2. Şimşek-Yavuz S, Akar AR, Aydoğdu S, et al. İnfektif Endokarditin Tanısı, Tedavisi ve Önlenmesi: Ulusal Uzlaşı Raporu. Klimik Derg 2019; 32: 2-116. DOI;10.5152/kd.2019.51
3. Zencirkiran Agus H, Kahraman S, Arslan C, et al. Characterization, epidemiological profile and risk factors for clinical outcome of infective endocarditis from a tertiary care centre in Turkey.
Infect Dis (Lond). 2019 Oct;51(10):738-744. doi: 10.1080/23744235.2019.1646431. Epub 2019 Jul 31. PMID: 31364901.
4. Çalık AN, Özlük ÖA, Karataş M, et al. Endocarditis-TR: Diagnosis, treatment, and prognosis of the infective endocarditis patients admitting tertiary centres of Turkey. Turk J Med Sci. 2022
Apr;52(2):445-455. doi: 10.55730/1300-0144.5332. Epub 2022 Apr 14. PMID: 36161622; PMCID: PMC10381203.
5. Sarıcaoğlu EM. Uygun-Kızmaz Y, Azap Ö, et al. COVID-19 Pandemisinin infektif endokardit epidemiyolojisi, klinik, mikrobiyolojik ve prognostic özellikleri üzerine etkisi. KLİMİK 2023
Kongre Kitabı, 2023. Sözel Sunum 32; 312-313.
6. Gouriet F, Chaudet H, Gautret P, et al. Endocarditis in the Mediterranean Basin. New Microbes New Infect. 2018;26:S43-S51.
7. Sengupta SP, Prendergast B, Laroche C, et al. Socioeconomic variations determine the clinical presentation, aetiology, and outcome of infective endocarditis: a prospective cohort study from
the ESC-EORP EURO-ENDO (European Infective Endocarditis) registry. Eur Heart J Qual Care Clin Outcomes. 2022 Dec 13;9(1):85-96. doi: 10.1093/ehjqcco/qcac012. PMID: 35278091.
8. Global oral health status report: towards universal health coverage for oral health by 2030. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. https://www.who.int/
team/noncommunicable-diseases/global-status-report-on-oral-health-2022/
9. Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. doi: 10.1093/eurheartj/ehad193. Erra-
tum in: Eur Heart J. 2023 Sep 20;: Erratum in: Eur Heart J. 2024 Jan 1;45(1):56. PMID: 37622656.
10. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years. N Engl J Med. 2023 Nov 23;389(21):1949-1960. doi: 10.1056/NEJ-
Moa2307447.
11. Blomström-Lundqvist C, Traykov V, Erba PA, et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implan-
table electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), Inter-
national Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European
Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020 Jun 1;41(21):2012-2032. doi: 10.1093/eurheartj/ehaa010.
12. Baskerville CA, Hanrahan BB, Burke AJ, et al. Infective endocarditis and rheumatic heart disease in the north of Australia. Heart Lung Circ. 2012;21(1):36-41.
13. Østergaard L, Valeur N, Wang A, et al. Incidence of infective endocarditis in patients considered at moderate risk. Eur Heart J. 2019;40(17):1355.
14. Katan O, Michelena HI, Avierinos JF, et al. Incidence and Predictors of Infective Endocarditis in Mitral Valve Prolapse: A Population-Based Study. Mayo Clin Proc. 2016;91(3):336-42.
15. Zegri-Reiriz I, de Alarcon A, Munoz P, et al. Infective Endocarditis in Patients With Bicuspid Aortic Valve or Mitral Valve Prolapse. J Am Coll Cardiol. 2018 19;71(24):2731-40.
16. Wurcel AG, Anderson JE, Chui KK, et al. Increasing Infectious Endocarditis Admissions Among Young People Who Inject Drugs. Open Forum Infect Dis. 2016;3(3):ofw157.
17. Chaudry MS, Carlson N, Gislason GH, et al. Risk of Infective Endocarditis in Patients with End Stage Renal Disease. Clin J Am Soc Nephrol. 2017;12(11):1814-22.
18. Ruttmann E, Bonatti H, Legit C, et al. Severe endocarditis in transplant recipients–an epidemiologic study. Transpl Int. 2005 Jun;18(6):690-6. PubMed PMID: 15910295. Epub 2005/05/25.
19. Castillo FJ, Anguita M, Castillo JC, Ruiz M, Mesa D, Suárez de Lezo J. Changes in Clinical Profile, Epidemiology and Prognosis of Left-sided Native-valve Infective Endocarditis Without
Predisposing Heart Conditions. Rev Esp Cardiol (Engl Ed). 2015;68(5):445. Epub 2015 Mar 16.
20. Olmos C, Vilacosta I, Fernandez C, et al. Comparison of clinical features of left-sided infective endocarditis involving previously normal versus previously abnormal valves. Am J Cardiol.
2014;114(2):278-83.
21. Holland TL, Bayer AS, Fowler VG, Endocarditis and Intravascular Infections. In: Bennett JE, Dolin R, Blaser MJ, editors. In Mandell, Douglas, and Bennett’s Principles and Practice of Infec-
tious Diseases. 9th ed. Philadelphia: Elsevier Saunders; 2020. p. 1068-1108.
22. Aldman MH, Rasmussen M, Olaison L, Påhlman LI. Endocarditis due to Staphylococcus lugdunensis-a retrospective national registry-based study. Eur J Clin Microbiol Infect Dis. 2021
May;40(5):1103-1106. doi: 10.1007/s10096-020-04134-w. Epub 2020 Dec 30. PMID: 33378000; PMCID: PMC8084830.
23. Yukawa, S., Noguchi, T., Shinohara, K. et al. Characteristics and outcomes in adult patients with Staphylococcus lugdunensis bacteremia compared to patients with Staphylococcus epidermidis
and Staphylococcus aureus bacteremia: a retrospective study in a 16-year period at the university hospital, Japan. BMC Infect Dis 23, 269 (2023). https://doi.org/10.1186/s12879-023-08233-9
24. Fowler VG, Durack DT, Selton-Suty C, et al. The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke
Criteria. Clin Infect Dis. 2023 Aug 22;77(4):518-526. doi: 10.1093/cid/ciad271. Erratum in: Clin Infect Dis. 2023 Oct 13;77(8):1222. PMID: 37138445; PMCID: PMC10681650.
25. Boleij A, van Gelder M, Swinkels D, Tjalsma H. Clinical Importance of Streptococcus gallolyticus Infection Among Colorectal Cancer Patients: Systematic Review and Meta-analysis, Clinical
Infectious Diseases, Volume 53, Issue 9, 1 November 2011, Pages 870–878, https://doi.org/10.1093/cid/cir609
26. Kumar R, Herold JL, Schady D, et al. Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development. PLoS Pathog. 2017 Jul 13;13(7):e1006440. doi: 10.1371/journal.
ppat.1006440. PMID: 28704539; PMCID: PMC5509344.
27. Berge A, Kronberg K, Sunnerhagen T, Nilson BHK, Giske CG, Rasmussen M. Risk for Endocarditis in Bacteremia With Streptococcus-Like Bacteria: A Retrospective Population-Based Co-
hort Study. Open Forum Infect Dis. 2019 Oct 4;6(10):ofz437. doi: 10.1093/ofid/ofz437. PMID: 31667201; PMCID: PMC6814282.
28. Chamat-Hedemand S, Dahl A, Østergaard L, et al. Prevalence of Infective Endocarditis in Streptococcal Bloodstream Infections Is Dependent on Streptococcal Species. Circulation. 2020 Aug
25;142(8):720-730. doi: 10.1161/CIRCULATIONAHA.120.046723. Epub 2020 Jun 25. PMID: 32580572.
29. Dahl A, Fowler VG, Miro JM, Bruun NE. Sign of the Times: Updating Infective Endocarditis Diagnostic Criteria to Recognize Enterococcus faecalis as a Typical Endocarditis Bacterium. Clin
Infect Dis. 2022 Sep 29;75(6):1097-1102. doi: 10.1093/cid/ciac181. PMID: 35262664.
30. Pericas JM, Corredoira J, Moreno A, et al. Relationship Between Enterococcus faecalis Infective Endocarditis and Colorectal Neoplasm: Preliminary Results From a Cohort of 154 Patients.
Rev Esp Cardiol (Engl Ed). 2017;70(6):451-8.
31. Sunnerhagen T, Törnell A, Vikbrant M, Nilson B, Rasmussen M. HANDOC: A Handy Score to Determine the Need for Echocardiography in Non-β-Hemolytic Streptococcal Bacteremia. Clin
Infect Dis. 2018 Feb 10;66(5):693-698. doi: 10.1093/cid/cix880. PMID: 29040411.
32. Calderón-Parra J, Diego-Yagüe I, Santamarina-Alcantud B, et al. Unreliability of Clinical Prediction Rules to Exclude without Echocardiography Infective Endocarditis in Staphylococcus
aureus Bacteremia. J Clin Med. 2022 Mar 9;11(6):1502. doi: 10.3390/jcm11061502.
33. Kahn F, Resman F, Bergmark S, et al. Time to blood culture positivity in Staphylococcus aureus bacteraemia to determine risk of infective endocarditis. Clin Microbiol Infect. 2021
Sep;27(9):1345.e7-1345.e12. doi: 10.1016/j.cmi.2020.11.007. Epub 2020 Nov 13. PMID: 33197608.
34. Papadimitriou-Olivgeris M, Monney P, Mueller L, Senn L, Guery B. The LAUsanne STAPHylococcus aureus ENdocarditis (LAUSTAPHEN) score: A prediction score to estimate initial risk
for infective endocarditis in patients with S. aureus bacteremia. Front Cardiovasc Med. 2022 Dec 9;9:961579. doi: 10.3389/fcvm.2022.961579.
35. Simos PA, Holland DJ, Stewart A, et al. Clinical prediction scores and the utility of time to blood culture positivity in stratifying the risk of infective endocarditis in Staphylococcus aureus
bacteraemia. J Antimicrob Chemother. 2022 Jun 29;77(7):2003-2010. doi: 10.1093/jac/dkac129. PMID: 35425988.
36. Sekar P, Johnson JR, Thurn JR, et al. Comparative Sensitivity of Transthoracic and Transesophageal Echocardiography in Diagnosis of Infective Endocarditis Among Veterans With Staphylo-
coccus aureus Bacteremia. Open Forum Infect Dis. 2017 Feb 22;4(2):ofx035. doi: 10.1093/ofid/ofx035. PMID: 28470017; PMCID: PMC5407216.
37. Goto M, Schweizer ML, Vaughan-Sarrazin MS, et al. Association of Evidence-Based Care Processes With Mortality in Staphylococcus aureus Bacteremia at Veterans Health Administration
Hospitals, 2003-2014. JAMA Intern Med. 2017;177(10):1489–1497. doi:10.1001/jamainternmed.2017.3958
38. Yildiz H, Reychler G, Rodriguez-Villalobos H, et al. Mortality in patients with high risk Staphylococcus aureus bacteremia undergoing or not PET-CT: A single center experience. J Infect
Chemother. 2019 Nov;25(11):880-885. doi: 10.1016/j.jiac.2019.04.016.
39. Hess S. [18F]FDG-PET/CT in patients with bacteremia: Clinical impact on patient management and outcome. Front Med (Lausanne). 2023 Mar 29;10:1157692. doi: 10.3389/fmed.2023.1157692
40. Bouza E, Kestler M, Beca T, et al. The NOVA score: a proposal to reduce the need for transesophageal echocardiography in patients with enterococcal bacteremia. Clin Infect Dis. 2015;60(4):528-
35.
41. Berge A, Krantz A, Ostlund H, Naucler P, Rasmussen M. The DENOVA score efficiently identifies patients with monomicrobial Enterococcus faecalis bacteremia where echocardiography is
not necessary. Infection. 2019;47(1):45-50.
42. Maskarinec SA, Thaden JT, Cyr DD, Ruffin F, Souli M, Fowler VG. The Risk of Cardiac Device-Related Infection in Bacteremic Patients Is Species Specific: Results of a 12-Year Prospective Cohort.
Open Forum Infect Dis. 2017 Jun 21;4(3):ofx132. doi: 10.1093/ofid/ofx132. PMID: 28852678; PMCID: PMC5570037.
43. Banzon JM, Rehm SJ, Gordon SM, Hussain ST, Pettersson GB, Shrestha NK. Propionibacterium acnes endocarditis: a case series. Clin Microbiol Infect. 2017 Jun;23(6):396-399. doi: 10.1016/j.
cmi.2016.12.026. Epub 2017 Jan 3. PMID: 28057559.
44. Berisha B, Ragnarsson S, Olaison L, Rasmussen M. Microbiological etiology in prosthetic valve endocarditis: A nationwide registry study. J Intern Med. 2022 Sep;292(3):428-437. doi: 10.1111/
joim.13491. Epub 2022 Apr 19. PMID: 35373870; PMCID: PMC9541636.
45. Hasse B, Hannan MM, Keller PM, et al. International Society of Cardiovascular Infectious Diseases Guidelines for the Diagnosis, Treatment and Prevention of Disseminated Mycobacterium
chimaera Infection Following Cardiac Surgery with Cardiopulmonary Bypass. J Hosp Infect. 2020 Feb;104(2):214-235. doi: 10.1016/j.jhin.2019.10.009. Epub 2019 Nov 9. PMID: 31715282.
46. Jamil Y, Akinleye A, Mirzaei M, Lempel M, Farhat K, Pan S. Candida endocarditis: Update on management considerations. World J Cardiol. 2023 Oct 26;15(10):469-478. doi: 10.4330/wjc.v15.
i10.469. PMID: 37900901; PMCID: PMC10600790.
47. Berisha B, Ragnarsson S, Olaison L, Rasmussen M. Microbiological etiology in prosthetic valve endocarditis: A nationwide registry study. J Intern Med. 2022 Sep;292(3):428-437. doi:
10.1111/joim.13491. Epub 2022 Apr 19. PMID: 35373870; PMCID: PMC9541636. Jana S. Endothelialization of cardiovascular devices. Acta Biomater. 2019 Nov;99:53-71. doi: 10.1016/j.
actbio.2019.08.042. Epub 2019 Aug 24. PMID: 31454565.
48. Chambers HF, Bayer ASB. Native-Valve Infective Endocarditis.N Engl J Med 2020;383:567-576. DOI: 10.1056/NEJMcp2000400
49. Holland, T., Baddour, L., Bayer, A. et al. Infective endocarditis. Nat Rev Dis Primers 2, 16059 (2016). Iung, B., Duval, X. Infective endocarditis: innovations in the management of an old disease.
Nat Rev Cardiol 16, 623–635 (2019). https://doi.org/10.1038/s41569-019-0215-0https://doi.org/10.1038/nrdp.2016.59
50. Naderi HR, Sheybani F, Erfani SS. Errors in diagnosis of infective endocarditis. Epidemiol Infect. 2018;146(3):394-400
51. Holcman K, Rubi´s P, Z abek A, et al. Advances in Molecular Imaging in Infective Endocarditis. Vaccines 2023, 11, 420. https://doi.org/10.3390/vaccines 11020420
52. Arockiam A.D, Agrawal A, El Dahdah J, et al. Contemporary Review of Multi-Modality Cardiac Imaging Evaluation of Infective Endocarditis. Life 2023, 13, 639. https://doi.org/ 10.3390/
life13030639
53. O’Gorman P, Nair L, Kisiel N, et al. Meta-analysis assessing the sensitivity and specificity of 18F-FDG PET/CT for the diagnosis of prosthetic valve endocarditis (PVE) using individual patient
data (IPD). Am Heart J. 2023 Jul;261:21-34. doi: 10.1016/j.ahj.2023.03.004. Epub 2023 Mar 18. PMID: 36934977.
54. Gomes A, van Geel PP, Santing M, et al. Imaging infective endocarditis: Adherence to a diagnostic flowchart and direct comparison of imaging techniques. J Nucl Cardiol. 2018 Jul 31; doi:
10.1007/s12350-018-1383-8.
55. Østergaard L, Voldstedlund M, Bruun NE, et al. Temporal Changes, Patient Characteristics, and Mortality, According to Microbiological Cause of Infective Endocarditis: A Nationwide Study.
J Am Heart Assoc. 2022 Aug 16;11(16):e025801. doi: 10.1161/JAHA.122.025801. Epub 2022 Aug 10. PMID: 35946455; PMCID: PMC9496298.
56. Cheng MP, Stenstrom R, Paquette K, et al. Blood Culture Results Before and After Antimicrobial Administration in Patients With Severe Manifestations of Sepsis: A Diagnostic Study. Ann
Intern Med. 2019 Oct 15;171(8):547-554. doi: 10.7326/M19-1696. Epub 2019 Sep 17. PMID: 31525774.pe
57. Liesman RM, Pritt BS, Maleszewski JJ, Patel R. Laboratory Diagnosis of Infective Endocarditis. J Clin Microbiol. 2017;55(9):2599-608.
58. Inojosa WO, Minniti G, Scotton PG. Is Mycobacterium chimaera Infection After Cardiac Surgery a Risk Factor for Bacterial Prosthetic Valve Endocarditis? Clin Infect Dis. 2020 Feb
14;70(5):991-992. doi: 10.1093/cid/ciz534. PMID: 31231760.
59. Haddad SF, DeSimone DC, Chesdachai S, Gerberi DJ, Baddour LM. Utility of Metagenomic Next-Generation Sequencing in Infective Endocarditis: A Systematic Review. Antibiotics (Basel).
2022 Dec 11;11(12):1798. doi: 10.3390/antibiotics11121798. PMID: 36551455; PMCID: PMC9774888.
60. Eichenberger EM, Degner N, Scott ER, et al. Microbial Cell-Free DNA Identifies the Causative Pathogen in Infective Endocarditis and Remains Detectable Longer Than Conventional Blood
Culture in Patients with Prior Antibiotic Therapy. Clin Infect Dis. 2023 Feb 8;76(3):e1492-e1500. doi: 10.1093/cid/ciac426. PMID: 35684984; PMCID: PMC10169441.
61. Mularoni A, Mikulska M, Barbera F, et al. Molecular Analysis With 16S rRNA PCR/Sanger Sequencing and Molecular Antibiogram Performed on DNA Extracted From Valve Improve Diag-
nosis and Targeted Therapy of Infective Endocarditis: A Prospective Study. Clin Infect Dis. 2023 Feb 8;76(3):e1484-e1491. doi: 10.1093/cid/ciac452. PMID: 35686318; PMCID: PMC9907470.
62. Kong WKF, Salsano A, Giacobbe DR, et al. Outcomes of culture-negative vs. culture-positive infective endocarditis: the ESC-EORP EURO-ENDO registry. Eur Heart J. 2022 Aug 1;43(29):2770-
2780. doi: 10.1093/eurheartj/ehac307. Erratum in: Eur Heart J. 2023 Jun 1;44(21):1909. PMID: 35695691; PMCID: PMC9459867.
63. García-Álvarez L, Sanz MM, Marín M, et al. Tropheryma whipplei endocarditis in Spain: Case reports of 17 prospective cases. Medicine (Baltimore). 2016 Jun;95(26):e4058. doi: 10.1097/
MD.0000000000004058. PMID: 27368042; PMCID: PMC4937956.
64. Ghanem-Zoubi N, Paul M, Szwarcwort M, Agmon Y, Kerner A. Screening for Q Fever in Patients Undergoing Transcatheter Aortic Valve Implantation, Israel, June 2018-May 2020. Emerg
Infect Dis. 2021 Aug;27(8):2205-2207. doi: 10.3201/eid2708.204963. PMID: 34287127; PMCID: PMC8314821.
65. van der Vaart TW, Bossuyt PMM, Durack DT, et al. External Validation of the 2023 Duke-International Society for Cardiovascular Infectious Diseases Diagnostic Criteria for Infective
Endocarditis. Clin Infect Dis. 2024 Apr 10;78(4):922-929. doi: 10.1093/cid/ciae033. PMID: 38330166; PMCID: PMC11006110.
66. Papadimitriou-Olivgeris M, Monney P, Frank M, et al. Evaluation of the 2023 Duke-International Society of Cardiovascular Infectious Diseases Criteria in a Multicenter Cohort of Patients
With Suspected Infective Endocarditis. Clin Infect Dis. 2024 Apr 10;78(4):949-955. doi: 10.1093/cid/ciae039. PMID: 38330243; PMCID: PMC11006096.
67. Roldan CA, Tolstrup K, Macias L, et al. Libman-Sacks Endocarditis: Detection, Characterization, and Clinical Correlates by Three-Dimensional Transesophageal Echocardiography. J Am Soc
Echocardiogr. 2015;28(7):770-9.
68. Park LP, Chu VH, Peterson G, et al. Validated Risk Score for Predicting 6-Month Mortality in Infective Endocarditis. J Am Heart Assoc. 2016;5(4):e003016.
69. Wald-Dickler N, Holtom PD, Phillips MC, et al. Oral Is the New IV. Challenging Decades of Blood and Bone Infection Dogma: A Systematic Review. Am J Med. 2022 Mar;135(3):369-379.e1.
doi: 10.1016/j.amjmed.2021.10.007.
70. Carter-Storch R, Pries-Heje MM, Povlsen JA, et al. Association Between Vegetation Size And Outcome In The POET Trial. Am J Cardiol. 2024 May 2:S0002-9149(24)00338-2. doi: 10.1016/j.
amjcard.2024.04.058
71. Rybak M, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the
American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists,
American Journal of Health-System Pharmacy, Volume 77, Issue 11, 1 June 2020, Pages 835–864, https://doi.org/10.1093/ajhp/zxaa036
72. Fernandez-Hidalgo N, Almirante B, Tornos P, et al. Prognosis of left-sided infective endocarditis in patients transferred to a tertiary-care hospital–prospective analysis of referral bias and
influence of inadequate antimicrobial treatment. Clin Microbiol Infect. 2011;17(5):769-75.
73. Garcia-de-la-Maria C, Pericas JM, Del Rio A, et al. Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to dap-
tomycin. Antimicrob Agents Chemother. 2013;57(5):2319-25.
74. Simsek-Yavuz S, Sensoy A, Kasikcioglu H, et al. Infective endocarditis in Turkey: aetiology, clinical features, and analysis of risk factors for mortality in 325 cases. Int J Infect Dis. 2015;30:106-
14.
75. Süzük S, Kaşkatepe B, Çetin M. Antimicrobial susceptibility against penicillin, ampicillin and vancomycin of viridans group Streptococcus in oral microbiota of patients at risk of infective
endocarditis. Le Infezioni in Medicina. 2016;24(3):190-3.
76. Pericàs JM, Nathavitharana R, Garcia-de-la-Mària C. Endocarditis Caused by Highly Penicillin-Resistant Viridans Group Streptococci: Still Room for Vancomycin-Based Regimens. Antimic-
rob Agents Chemother. 2019 Jul 25;63(8):e00516-19. doi: 10.1128/AAC.00516-19.
77. Weis S, Kesselmeier M, Davis JS, et al. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2019
Jul;25(7):818-827. doi: 10.1016/j.cmi.2019.03.010. Epub 2019 Mar 27. PMID: 30928559.
78. Lecomte R, Bourreau A, Deschanvres C, et al. Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis:
a post hoc analysis of a prospective multicentre French cohort study. Clin Microbiol Infect. 2021 Jul;27(7):1015-1021. doi: 10.1016/j.cmi.2020.08.044. Epub 2020 Sep 17. PMID: 32950711
79. Lo CK, Sritharan A, Zhang J, et al. Clinical significance of cefazolin inoculum effect in serious MSSA infections: a systematic review. JAC Antimicrob Resist. 2024 May 6;6(3):dlae069. doi:
10.1093/jacamr/dlae069. PMID: 38716403; PMCID: PMC11073751.
80. Antosz K, Battle S, Chang J, Scheetz MH, Al-Hasan M, Bookstaver PB. Cefazolin in the treatment of central nervous system infections: A narrative review and recommendation. Pharmacot-
herapy. 2023 Jan;43(1):85-95. doi: 10.1002/phar.2750. Epub 2023 Jan 22. PMID: 36521869.
81. Le Turnier P, Gregoire M, Deslandes G, et al. Should we reconsider cefazolin for treating staphylococcal meningitis? A retrospective analysis of cefazolin and cloxacillin cerebrospinal fluid
levels in patients treated for staphylococcal meningitis. Clin Microbiol Infect. 2020 Oct;26(10):1415.e1-1415.e4. doi: 10.1016/j.cmi.2020.04.046. Epub 2020 May 8. PMID: 32437956.
82. Yetmar ZA, Khodadadi RB, Go JR, Chesdachai S, Abu Saleh OM. Post-treatment outcomes of ceftriaxone versus antistaphylococcal penicillins or cefazolin for definitive therapy of methicil-
lin-susceptible Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2023 Apr;42(4):423-430. doi: 10.1007/s10096-023-04575-z. Epub 2023 Feb 17. PMID: 36800065.
83. Alsowaida YS, Benitez G, Bin Saleh K, Almangour TA, Shehadeh F, Mylonakis E. Effectiveness and Safety of Ceftriaxone Compared to Standard of Care for Treatment of Bloodstream Infe-
ctions Due to Methicillin-Susceptible Staphylococcus aureus: A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2022 Mar 10;11(3):375. doi: 10.3390/antibiotics11030375. PMID:
35326838; PMCID: PMC8944781.
84. Paul M, Zemer-Wassercug N, Talker O, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect.
2011;17(10):1581-6.
85. Park GE, Ko JH, Cho SY, et al. Empirical combination of a beta-lactam to vancomycin may not improve outcomes of methicillin-susceptible Staphylococcus aureus bacteremia, compared to
vancomycin monotherapy. Eur J Clin Microbiol Infect Dis. 2017;36(7):1091-6.
86. Tong SYC, Lye DC, Yahav D, et al. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients
With MRSA Bacteremia: A Randomized Clinical Trial. JAMA. 2020 Feb 11;323(6):527-537. doi: 10.1001/jama.2020.0103. PMID: 32044943; PMCID: PMC7042887.
87. Cheng M, Lawandi A, Butler-Laporte G, et al. Adjunctive Daptomycin in the Treatment of Methicillin-susceptible Staphylococcus aureus Bacteremia: A Randomized, Controlled Trial, Clini-
cal Infectious Diseases, Volume 72, Issue 9, 1 May 2021, Pages e196–e203, https://doi.org/10.1093/cid/ciaa1000
88. Ishaq H, Tariq W, Talha KM, et al. Association between high vancomycin minimum inhibitory concentration and clinical outcomes in patients with methicillin-resistant Staphylococcus aureus bacte-
remia: a meta-analysis. Infection. 2021 Oct;49(5):803-811. doi: 10.1007/s15010-020-01568-4. Epub 2021 Jan 4. PMID: 33394368.
89. Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial
Chemotherapy. J Antimi.
90. García-de-la-Mària C, Gasch O, García-Gonzalez J, et al. The Combination of Daptomycin and Fosfomycin Has Synergistic, Potent, and Rapid Bactericidal Activity against Methicillin-Resis-
tant Staphylococcus aureus in a Rabbit Model of Experimental Endocarditis. Antimicrob Agents Chemother. 2018;65(25):6.
91. Wang C, Ye C, Liao L, Wang Z, Hu Y, Deng C, Liu L. Adjuvant β-Lactam Therapy Combined with Vancomycin or Daptomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: a
Systematic Review and Meta-analysis. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01377-20. doi: 10.1128/AAC.01377-20. PMID: 32839217; PMCID: PMC7577142.
92. Holubar M, Meng L, Alegria W, Deresinski S. Bacteremia due to Methicillin-Resistant Staphylococcus aureus: An Update on New Therapeutic Approaches. Infect Dis Clin North Am. 2020
Dec;34(4):849-861. doi: 10.1016/j.idc.2020.04.003. Epub 2020 Sep 30. PMID: 33011050.
93. Geriak M, Haddad F, Rizvi K, et al. Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus
Bacteremia. Antimicrob Agents Chemother. 2019 Apr 25;63(5):e02483-18. doi: 10.1128/AAC.02483-18. PMID: 30858203; PMCID: PMC6496065.
94. Minter DJ, Appa A, Chambers HF, Doernberg SB. Contemporary Management of Staphylococcus aureus Bacteremia-Controversies in Clinical Practice. Clin Infect Dis. 2023 Nov
30;77(11):e57-e68. doi: 10.1093/cid/ciad500. PMID: 37950887.
95. Holland TL, Cosgrove SE, Doernberg SB, et al Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia. N Engl J Med. 2023 Oct 12;389(15):1390-1401. doi: 10.1056/
NEJMoa2300220. Epub 2023 Sep 27. PMID: 37754204.
96. Wilsey HA, Burgess DR, Burgess DS. Focusing the Lens on the CAMERA Concepts: Early Combination β-Lactam and Vancomycin Therapy in Methicillin-Resistant Staphylococcus aureus
Bacteremia. Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00360-20. doi: 10.1128/AAC.00360-20. PMID: 32366709; PMCID: PMC7318021.
97. Casalta JP, Zaratzian C, Hubert S, et al. Treatment of Staphylococcus aureus endocarditis with high doses of trimethoprim/sulfamethoxazole and clindamycin-Preliminary report. Int J Anti-
microb Agents. 2013 ;42(2):190-1.
98. Rivoisy C, Vena A, Schaeffer L, et al. Prosthetic Valve Candida spp. Endocarditis: New Insights Into Long-term Prognosis-The ESCAPE Study. Clin Infect Dis. 2018 ;66(6):825-32.
99. Mohananey D, Mohadjer A, Pettersson G, et al. Association of Vegetation Size With Embolic Risk in Patients With Infective Endocarditis: A Systematic Review and Meta-analysis. JAMA
Intern Med. 2018 ;178(4):502-10.
100. Fauchier L, Bisson A, Herbert J, et al. Incidence and outcomes of infective endocarditis after transcatheter aortic valve implantation versus surgical aortic valve replacement. Clin Microbiol
Infect. 2020 Oct;26(10):1368-1374. doi: 10.1016/j.cmi.2020.01.036. Epub 2020 Feb 6. PMID: 32036047.
101. Del Val D, Panagides V, Mestres CA, Miró JM, Rodés-Cabau J. Infective Endocarditis After Transcatheter Aortic Valve Replacement: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023
Jan 31;81(4):394-412. doi: 10.1016/j.jacc.2022.11.028. PMID: 36697140.
102. Schranz AJ, Fleischauer A, Chu VH, Wu LT, Rosen DL. Trends in Drug Use-Associated Infective Endocarditis and Heart Valve Surgery, 2007 to 2017: A Study of Statewide Discharge Data.
Ann Intern Med. 2018 Dec 4. doi: 10.7326/M18-2124
103. Williams ML, Doyle MP, McNamara N, Tardo D, Mathew M, Robinson B. Epidemiology of infective endocarditis before versus after change of international guidelines: a systematic review.
Ther Adv Cardiovasc Dis. 2021 Jan-Dec;15:17539447211002687. doi: 10.1177/17539447211002687. PMID: 33784909; PMCID: PMC8020745.
104. Lean SSH, Jou E, Ho JSY, Jou EGL. Prophylactic antibiotic use for infective endocarditis: a systematic review and meta-analysis. BMJ Open. 2023 Aug 22;13(8):e077026. doi: 10.1136/bmjo-
pen-2023-077026. PMID: 37607797; PMCID: PMC10445353.
105. Thornhill MH, Gibson TB, Yoon F, et al. Antibiotic prophylaxis against infective endocarditis before invasive dental procedures. J Am Coll Cardiol 2022;80:1029–41.
106. Thornhill MH, Gibson TB, Yoon F, et al. Endocarditis, invasive dental procedures, and antibiotic prophylaxis efficacy in US Medicaid patients. Oral Dis 27, 2023.
107. Sperotto F, France K, Gobbo M, et al. Antibiotic Prophylaxis and Infective Endocarditis Incidence Following Invasive Dental Procedures: A Systematic Review and Meta-Analysis. JAMA
Cardiol. 2024 Apr 6:e240873. doi: 10.1001/jamacardio.2024.0873. Epub ahead of print. PMID: 38581643; PMCID: PMC10999003
108. Janszky I, Gémes K, Ahnve S, Asgeirsson H, Möller J. Invasive Procedures Associated With the Development of Infective Endocarditis. J Am Coll Cardiol. 2018 Jun 19;71(24):2744-2752. doi:
10.1016/j.jacc.2018.03.532. PMID: 29903348.
109. Thornhill MH, Crum A, Campbell R, et al. Temporal association between invasive procedures and infective endocarditis. Heart. 2023 Jan 11;109(3):223-231. doi: 10.1136/heartjnl-2022-321519.
PMID: 36137742; PMCID: PMC9872236.
110. Wilson WR, Gewitz M, Lockhart PB, et al. Prevention of Viridans Group Streptococcal Infective Endocarditis: A Scientific Statement From the American Heart Association. Circulation.
2021;143(20):e963-e978. doi: 10.1161/CIR.0000000000000969.
111. Dayer MJ, Thornhill M, Baddour LM. Antibiotic prophylaxis for patients at risk of infective endocarditis: an increasing evidence base? Br J Cardiol. 2023 Feb 21;30(1):6. doi: 10.5837/
bjc.2023.006. PMID: 37705833; PMCID: PMC10495760.
112. Lockhart PB, Brennan MT, Thornhill M, et al. Poor oral hygiene as a risk factor for infective endocarditis–related bacteremia. The Journal of the American Dental Association. 2009;140(10):1238-
44.
113. Hassanzadeh H, Baber J, Begier E, et al. STaphylococcus aureus suRgical Inpatient Vaccine Efficacy Investigator Team. Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery:
The STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) Randomized Clinical Trial. Clin Infect Dis. 2023 Jul 26;77(2):312-320. doi: 10.1093/cid/ciad218. PMID: 37125490;
PMCID: PMC10371312.